FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379280770> ?p ?o ?g. }

• W4379280770 endingPage "9070" @default.
• W4379280770 startingPage "9070" @default.
• W4379280770 abstract "9070 Background: Oncogenic activation of MET is a common mechanism of acquired resistance to EGFR TKIs in patients (pts) with EGFRm NSCLC, with MET amplification (amp) constituting the most frequent cause of bypass pathway activation. Currently, there are no approved targeted treatment options for these pts. Data from the Phase II INSIGHT (NCT01982955) and INSIGHT 2 (NCT03940703) studies indicate the combination of the selective MET TKI tepotinib plus an EGFR TKI has encouraging activity. We present a case series of pts with EGFRm MET-altered NSCLC receiving tepotinib plus an EGFR TKI outside of clinical trials. Methods: Access to tepotinib was provided to pts with EGFRm MET-altered NSCLC and resistance to EGFR TKIs through unsolicited compassionate use requests. All pts received tepotinib (500 mg [450 mg active moiety] once daily; first dose by Oct 2022) plus an EGFR TKI. Participating physicians provided case information up to January 2023. Results: 28 cases of pts with EGFRm NSCLC and MET alterations who received tepotinib plus an EGFR TKI were collated. 21 pts had METamp after EGFR TKI treatment, 5 had MET overexpression, and 2 had MET exon 14 skipping. Pts were aged 41–86 years, 15 were Asian, 13 were white, 19 were female, 8 had smoking history, and all had adenocarcinoma histology. METamp was detected by tissue biopsy in 17 pts, and liquid biopsy in 4 pts. Of 12 pts with METamp detected by FISH, gene copy number ranged from 5.3–33.4, and MET:CEP7 ratio from 0.7–15.1. EGFR TKIs received in combination with tepotinib were osimertinib (n = 21, 19 of whom received prior osimertinib), gefitinib (n = 6), dacomitinib (n = 1), afatinib (n = 1), with 1 pt received gefitinib followed by osimertinib. Tepotinib plus EGFR TKI was received by 9 pts as second-line, 9 as third-line, and 10 as fourth-or-later line. Median treatment duration was 8.8 months (range 1.3–20.6), with treatment ongoing in 13 pts (10 with current duration ≥10 months). Per the physician’s assessment, 25/28 pts (89%) had clinical benefit, 16 of whom (57%) were considered to have a partial response (PR). Clinical benefit was reported in 18/21 (86%) pts with METamp (12 PR, 57%), in 5/5 with MET overexpression (2 PR), and 2/2 with MET exon 14 skipping (2 PR). The most reported adverse event (AE) considered related to tepotinib was edema in 15 pts (most commonly peripheral edema). Grade 3 AEs related to tepotinib were reported in 5 pts (including Grade 3 edema in 2 pts), 1 of whom discontinued the combination due to Grade 3 pneumonitis. Conclusions: Tepotinib plus an EGFR TKI showed promising clinical activity in pts with MET-altered NSCLC who have progressed on a previous EGFR TKI, including those with several lines of prior treatment. Clinical benefit was observed irrespective of MET alteration type in this case series of pts treated outside of clinical trials, with a large proportion of patients continuing to benefit from ongoing treatment." @default.
• W4379280770 created "2023-06-05" @default.
• W4379280770 creator A5001400077 @default.
• W4379280770 creator A5005972479 @default.
• W4379280770 creator A5007462622 @default.
• W4379280770 creator A5009342385 @default.
• W4379280770 creator A5011828578 @default.
• W4379280770 creator A5012226414 @default.
• W4379280770 creator A5013909542 @default.
• W4379280770 creator A5026944178 @default.
• W4379280770 creator A5039944755 @default.
• W4379280770 creator A5047628204 @default.
• W4379280770 creator A5055246540 @default.
• W4379280770 creator A5060513789 @default.
• W4379280770 creator A5072143967 @default.
• W4379280770 creator A5073440860 @default.
• W4379280770 creator A5073544115 @default.
• W4379280770 creator A5074784103 @default.
• W4379280770 creator A5076347327 @default.
• W4379280770 creator A5080098952 @default.
• W4379280770 creator A5080545171 @default.
• W4379280770 creator A5087617307 @default.
• W4379280770 date "2023-06-01" @default.
• W4379280770 modified "2023-10-01" @default.
• W4379280770 title "Patients with <i>EGFR</i> mutant (m) MET-altered NSCLC receiving tepotinib with an EGFR tyrosine kinase inhibitor (TKI): A case series." @default.
• W4379280770 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.9070" @default.
• W4379280770 hasPublicationYear "2023" @default.
• W4379280770 type Work @default.
• W4379280770 citedByCount "0" @default.
• W4379280770 crossrefType "journal-article" @default.
• W4379280770 hasAuthorship W4379280770A5001400077 @default.
• W4379280770 hasAuthorship W4379280770A5005972479 @default.
• W4379280770 hasAuthorship W4379280770A5007462622 @default.
• W4379280770 hasAuthorship W4379280770A5009342385 @default.
• W4379280770 hasAuthorship W4379280770A5011828578 @default.
• W4379280770 hasAuthorship W4379280770A5012226414 @default.
• W4379280770 hasAuthorship W4379280770A5013909542 @default.
• W4379280770 hasAuthorship W4379280770A5026944178 @default.
• W4379280770 hasAuthorship W4379280770A5039944755 @default.
• W4379280770 hasAuthorship W4379280770A5047628204 @default.
• W4379280770 hasAuthorship W4379280770A5055246540 @default.
• W4379280770 hasAuthorship W4379280770A5060513789 @default.
• W4379280770 hasAuthorship W4379280770A5072143967 @default.
• W4379280770 hasAuthorship W4379280770A5073440860 @default.
• W4379280770 hasAuthorship W4379280770A5073544115 @default.
• W4379280770 hasAuthorship W4379280770A5074784103 @default.
• W4379280770 hasAuthorship W4379280770A5076347327 @default.
• W4379280770 hasAuthorship W4379280770A5080098952 @default.
• W4379280770 hasAuthorship W4379280770A5080545171 @default.
• W4379280770 hasAuthorship W4379280770A5087617307 @default.
• W4379280770 hasConcept C121608353 @default.
• W4379280770 hasConcept C126322002 @default.
• W4379280770 hasConcept C143998085 @default.
• W4379280770 hasConcept C2777506169 @default.
• W4379280770 hasConcept C2778820342 @default.
• W4379280770 hasConcept C2779438470 @default.
• W4379280770 hasConcept C2780580887 @default.
• W4379280770 hasConcept C2781187634 @default.
• W4379280770 hasConcept C526805850 @default.
• W4379280770 hasConcept C71924100 @default.
• W4379280770 hasConceptScore W4379280770C121608353 @default.
• W4379280770 hasConceptScore W4379280770C126322002 @default.
• W4379280770 hasConceptScore W4379280770C143998085 @default.
• W4379280770 hasConceptScore W4379280770C2777506169 @default.
• W4379280770 hasConceptScore W4379280770C2778820342 @default.
• W4379280770 hasConceptScore W4379280770C2779438470 @default.
• W4379280770 hasConceptScore W4379280770C2780580887 @default.
• W4379280770 hasConceptScore W4379280770C2781187634 @default.
• W4379280770 hasConceptScore W4379280770C526805850 @default.
• W4379280770 hasConceptScore W4379280770C71924100 @default.
• W4379280770 hasIssue "16_suppl" @default.
• W4379280770 hasLocation W43792807701 @default.
• W4379280770 hasOpenAccess W4379280770 @default.
• W4379280770 hasPrimaryLocation W43792807701 @default.
• W4379280770 hasRelatedWork W121706947 @default.
• W4379280770 hasRelatedWork W2017389411 @default.
• W4379280770 hasRelatedWork W2017576089 @default.
• W4379280770 hasRelatedWork W2048634696 @default.
• W4379280770 hasRelatedWork W2590252361 @default.
• W4379280770 hasRelatedWork W2604771463 @default.
• W4379280770 hasRelatedWork W2767618589 @default.
• W4379280770 hasRelatedWork W2981712864 @default.
• W4379280770 hasRelatedWork W3000010538 @default.
• W4379280770 hasRelatedWork W640993906 @default.
• W4379280770 hasVolume "41" @default.
• W4379280770 isParatext "false" @default.
• W4379280770 isRetracted "false" @default.
• W4379280770 workType "article" @default.